Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors

The majority of human cancers harbour mutations promoting activation of the Akt protein kinase, and Akt inhibitors are being evaluated in clinical trials. An important question concerns the understanding of the innate mechanisms that confer resistance of tumour cells to Akt inhibitors. SGK (serum- and glucocorticoid-regulated kinase) is closely related to Akt and controlled by identical upstream regulators {PI3K (phosphoinositide 3-kinase), PDK1 (phosphoinositide-dependent kinase 1) and mTORC2 [mTOR (mammalian target of rapamycin) complex 2]}. Mutations that trigger activation of Akt would also stimulate SGK. Moreover, Akt and SGK possess analogous substrate specificities and are likely to phosphorylate overlapping substrates to promote proliferation. To investigate whether cancers possessing high SGK activity could possess innate resistance to Akt-specific inhibitors (that do not target SGK), we analysed SGK levels and sensitivity of a panel of breast cancer cells towards two distinct Akt inhibitors currently in clinical trials (AZD5363 and MK-2206). This revealed a number of Akt-inhibitor-resistant lines displaying markedly elevated SGK1 that also exhibited significant phosphorylation of the SGK1 substrate NDRG1 [N-Myc (neuroblastoma-derived Myc) downstream-regulated gene 1]. In contrast, most Akt-inhibitor-sensitive cell lines displayed low/undetectable levels of SGK1. Intriguingly, despite low SGK1 levels, several Akt-inhibitor-sensitive cells showed marked NDRG1 phosphorylation that was, unlike in the resistant cells, suppressed by Akt inhibitors. SGK1 knockdown markedly reduced proliferation of Akt-inhibitor-resistant, but not -sensitive, cells. Furthermore, treatment of Akt-inhibitor-resistant cells with an mTOR inhibitor suppressed proliferation and led to inhibition of SGK1. The results of the present study suggest that monitoring SGK1 levels as well as responses of NDRG1 phosphorylation to Akt inhibitor administration could have a use in predicting the sensitivity of tumours to compounds that target Akt. Our findings highlight the therapeutic potential that SGK inhibitors or dual Akt/SGK inhibitors might have for treatment of cancers displaying elevated SGK activity.

[1]  G. Firestone,et al.  Immediate-early transcriptional regulation and rapid mRNA turnover of a putative serine/threonine protein kinase. , 1993, The Journal of biological chemistry.

[2]  A. C. Maiyar,et al.  Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum , 1993, Molecular and cellular biology.

[3]  Ken Saito,et al.  Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression , 2004, Oncogene.

[4]  Jorma Isola,et al.  Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. , 2004, Molecular cancer therapeutics.

[5]  C. Graham,et al.  Hypoxia induces the expression of a 43-kDa protein (PROXY-1) in normal and malignant cells. , 2000, Biochemical and biophysical research communications.

[6]  Deanna R. Brickley,et al.  Ubiquitin Modification of Serum and Glucocorticoid-induced Protein Kinase-1 (SGK-1)* , 2002, The Journal of Biological Chemistry.

[7]  J. Isola,et al.  Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. , 2010, Cancer letters.

[8]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[9]  A. Bogusz,et al.  A novel N‐terminal hydrophobic motif mediates constitutive degradation of serum‐ and glucocorticoid‐induced kinase‐1 by the ubiquitin–proteasome pathway , 2006, The FEBS journal.

[10]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[11]  D. Alessi,et al.  Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. , 2011, The Biochemical journal.

[12]  R. Penner,et al.  Stimulation of Ca2+‐channel Orai1/STIM1 by serum‐and glucocorticoid‐inducible kinase 1 (SGK1) , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[14]  Ayaz Najafov,et al.  Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. , 2011, The Biochemical journal.

[15]  P. Cohen,et al.  Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. , 2004, The Biochemical journal.

[16]  K. Salnikow,et al.  Cap43, a novel gene specifically induced by Ni2+ compounds. , 1998, Cancer research.

[17]  P. Cohen,et al.  Identification of different specificity requirements between SGK1 and PKBα , 2005, FEBS letters.

[18]  Carlos L Arteaga,et al.  Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer , 2011, Breast Cancer Research.

[19]  Mieke Schutte,et al.  Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines , 2007, Molecular Cancer Research.

[20]  C. Schmidt,et al.  SGK1 Sensitivity of Platelet Migration , 2012, Cellular Physiology and Biochemistry.

[21]  David Olmos,et al.  First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Aaronson,et al.  Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. , 1998, Cancer research.

[23]  Brian A. Hemmings,et al.  Protein Kinase SGK Mediates Survival Signals by Phosphorylating the Forkhead Transcription Factor FKHRL1 (FOXO3a) , 2001, Molecular and Cellular Biology.

[24]  D. Alessi,et al.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.

[25]  P. Cohen,et al.  Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. , 1999, The Biochemical journal.

[26]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[27]  D. Alessi,et al.  The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.

[28]  Wei Wu,et al.  Microarray Analysis Reveals Glucocorticoid-Regulated Survival Genes That Are Associated With Inhibition of Apoptosis in Breast Epithelial Cells , 2004, Cancer Research.

[29]  P. Cohen,et al.  Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase‐1 and p70 S6 kinase , 1996, FEBS letters.

[30]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[31]  Maria Deak,et al.  The PIF‐binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB , 2001, The EMBO journal.

[32]  F. Artunc,et al.  The physiological impact of the serum and glucocorticoid-inducible kinase SGK1 , 2009, Current opinion in nephrology and hypertension.

[33]  W. Criekinge,et al.  The N‐myc downstream regulated gene (NDRG) family: diverse functions, multiple applications , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  H. Kondoh,et al.  N-myc-dependent repression of Ndr1, a gene identified by direct subtraction of whole mouse embryo cDNAs between wild type and N-myc mutant , 1999, Mechanisms of Development.

[35]  D. Alessi,et al.  Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. , 2012, The Biochemical journal.

[36]  Philip R. Cohen,et al.  Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase. , 1999, The Biochemical journal.

[37]  A. Rehemtulla,et al.  Characterization of fibroblast growth factor receptor 2 overexpression in the human breast cancer cell line SUM-52PE , 2000, Breast Cancer Research.

[38]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[39]  K. Abromeit.  Music Received , 2023, Notes.

[40]  T. Miyata,et al.  Homocysteine-respondent Genes in Vascular Endothelial Cells Identified by Differential Display Analysis , 1996, The Journal of Biological Chemistry.

[41]  Pixu Liu,et al.  Targeting the phosphoinositide 3-kinase pathway in cancer , 2009, Nature Reviews Drug Discovery.

[42]  Jing Li,et al.  Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background , 2012, Molecular Cancer Therapeutics.

[43]  Lisa L. Smith,et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. , 2010, Cancer research.

[44]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[45]  B. Taylor,et al.  Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). , 2010, Cancer research.